Boston Scientific stock receives consensus “buy” rating: 4 key notes

Analyst Ratings Network.com reported that Boston Scientific has received a consensus rating of “buy” from 24 research firms, according to WKRB News & Analysis.

Advertisement

Here are four key notes:

1. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $18.62.

2. The average 12-month price objective among brokerages, which updated their coverage on the stock in the last year, is $19.03.

3. Boston Scientific’s 50-day moving average is $17.55 and its 200-day moving average is $17.29.

4. The company’s market capitalization is $23.61 billion.

More articles on GI/endoscopy:
Cape Regional Health System opens new endoscopy center: 3 things to know
Top 20 top-selling drugs in June
NJ Digestive Healthcare Center wins innovation award

Advertisement

Next Up in GI & Endoscopy

  • As colonoscopy demand rises, driven in part by more diagnostic referrals for patients under 55, GI leaders are also seeing…

  • Medical device company and surgical equipment manufacturer ConMed plans to exit its gastroenterology product lines.  ConMed’s gastroenterology segment is projected…

Advertisement

Comments are closed.